Onaga Ryutaro, Enokida Tomohiro, Kuno Hirofumi, Hiyama Takashi, Okano Susumu, Fujisawa Takao, Tanaka Nobukazu, Hoshi Yuta, Kishida Takuma, Kuboki Ryo, Takeshita Naohiro, Tanaka Hideki, Nishino Hiroshi, Ito Makoto, Tahara Makoto
Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan; Department of Otolaryngology and Head and Neck Surgery, Jichi Medical University, Tochigi, Japan.
Department of Head and Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
Oral Oncol. 2025 Jun;165:107351. doi: 10.1016/j.oraloncology.2025.107351. Epub 2025 May 7.
Prognosis of locally advanced squamous cell carcinoma of the head and neck (LA-HNSCC) is poor, particularly in cases with extranodal extension. The Head and Neck Cancer International Group (HNCIG) recently published criteria for imaging-detected extranodal extension (iENE). Here, we aimed to clarify the significance of iENE in induction chemotherapy followed by chemoradiotherapy.
We retrospectively investigated patients with LA-HNSCC scheduled to receive induction chemotherapy followed by chemoradiotherapy between 2013 and 2022 at the National Cancer Center Hospital East, Japan. Two radiologists blindly annotated the grading of iENE for pretreatment computed tomography scans according to the HNCIG criteria.
Eighty-eight patients were identified, of whom 21 were categorized as iENE-negative and 67 as iENE-positive. The iENE-positive group showed a significantly poorer prognosis than the negative group for event-free survival (EFS) (hazard ratio [HR]; 2.92, 95% confidence interval [CI]; 1.15-7.43, log-rank p-value; 0.02) and overall survival (OS) (HR; 9.34, 95%CI; 1.26-69.3, log-rank p-value; 0.03). In multivariate analysis of variables at pretreatment and after induction chemotherapy, iENE positivity and non-response to induction chemotherapy were independently associated with adverse prognosis for EFS (iENE-positive: HR; 2.57, 95%CI; 1.01-6.57, p-value; 0.04. Non-response to induction chemotherapy: HR; 2.40, 95%CI; 1.31-4.40, p-value; 0.005) and OS (iENE-positive: HR; 8.17, 95%CI; 1.10-60.0, p-value; 0.04, non-response to induction chemotherapy: HR; 3.40, 95%CI; 1.46-8.28, p-value; 0.004).
The presence of iENE and non-response to induction chemotherapy were independently associated with poor prognosis for LA-HNSCC treated with induction chemotherapy followed by chemoradiotherapy.
局部晚期头颈部鳞状细胞癌(LA-HNSCC)的预后较差,尤其是伴有结外扩散的病例。头颈癌国际组织(HNCIG)最近公布了影像学检测到的结外扩散(iENE)标准。在此,我们旨在阐明iENE在诱导化疗后序贯放化疗中的意义。
我们回顾性调查了2013年至2022年期间在日本国立癌症中心东医院计划接受诱导化疗后序贯放化疗的LA-HNSCC患者。两名放射科医生根据HNCIG标准对治疗前计算机断层扫描的iENE分级进行盲法标注。
共纳入88例患者,其中21例被归类为iENE阴性,67例为iENE阳性。iENE阳性组的无事件生存期(EFS)(风险比[HR];2.92,95%置信区间[CI];1.15 - 7.43,对数秩p值;0.02)和总生存期(OS)(HR;9.34,95%CI;1.26 - 69.3,对数秩p值;0.03)的预后明显比阴性组差。在对治疗前和诱导化疗后的变量进行多因素分析时,iENE阳性和对诱导化疗无反应与EFS的不良预后独立相关(iENE阳性:HR;2.57,95%CI;1.01 - 6.57,p值;0.04。对诱导化疗无反应:HR;2.40,95%CI;1.31 - 4.40,p值;0.005)和OS(iENE阳性:HR;8.17,95%CI;1.10 - 60.0,p值;0.04,对诱导化疗无反应:HR;3.40,95%CI;1.46 - 8.28,p值;0.004)。
iENE的存在和对诱导化疗无反应与接受诱导化疗后序贯放化疗的LA-HNSCC的不良预后独立相关。